Sawai Group Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Sawai Group Holdings's earnings have been declining at an average annual rate of -17.4%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 0.3% per year. Sawai Group Holdings's return on equity is 6.2%, and it has net margins of 10.6%.
Anahtar bilgiler
-17.4%
Kazanç büyüme oranı
-17.4%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 3.4% |
| Gelir büyüme oranı | 0.3% |
| Özkaynak getirisi | 6.2% |
| Net Marj | 10.6% |
| Sonraki Kazanç Güncellemesi | 11 Nov 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?
Sep 04
Sawai Group Holdings Co., Ltd. (TSE:4887) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 12Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet
Jul 27Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?
May 28Is There An Opportunity With Sawai Group Holdings Co., Ltd.'s (TSE:4887) 41% Undervaluation?
Apr 22Is Sawai Group Holdings (TSE:4887) A Risky Investment?
Mar 06Gelir ve Gider Dağılımı
Sawai Group Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 168,201 | 17,756 | 20,064 | 11,746 |
| 31 Mar 24 | 176,862 | 17,218 | 23,244 | 12,189 |
| 31 Dec 23 | 185,309 | 17,709 | 23,836 | 12,885 |
| 30 Sep 23 | 191,324 | 14,545 | 26,481 | 14,460 |
| 30 Jun 23 | 205,102 | 12,513 | 31,556 | 15,688 |
| 31 Mar 23 | 200,344 | 12,667 | 30,156 | 16,090 |
| 31 Dec 22 | 196,280 | -33,307 | 31,584 | 14,414 |
| 30 Sep 22 | 192,928 | -31,031 | 31,458 | 14,767 |
| 30 Jun 22 | 191,561 | -30,904 | 31,719 | 15,468 |
| 31 Mar 22 | 193,816 | -28,269 | 32,499 | 16,456 |
| 31 Dec 21 | 193,149 | 10,835 | 34,082 | 16,952 |
| 30 Sep 21 | 194,349 | 10,962 | 34,937 | 15,367 |
| 30 Jun 21 | 193,763 | 13,177 | 34,933 | 14,697 |
| 31 Mar 21 | 187,219 | 12,340 | 34,851 | 13,397 |
| 31 Dec 20 | 184,968 | 19,348 | 47,706 | -158 |
| 30 Sep 20 | 182,228 | 19,107 | 47,214 | -203 |
| 30 Jun 20 | 179,345 | 18,313 | 47,240 | -629 |
| 31 Mar 20 | 182,537 | 19,279 | 33,888 | 12,974 |
| 31 Dec 19 | 186,610 | 19,891 | 27,821 | 15,982 |
| 30 Sep 19 | 186,030 | 19,831 | 27,312 | 16,067 |
| 30 Jun 19 | 186,177 | 20,554 | 26,892 | 17,130 |
| 31 Mar 19 | 184,341 | 19,376 | 32,380 | 16,671 |
| 31 Dec 18 | 189,526 | 16,777 | 21,606 | 24,692 |
| 30 Sep 18 | 186,102 | 15,743 | 26,104 | 21,488 |
| 30 Jun 18 | 179,720 | 14,619 | 28,062 | 17,588 |
| 31 Mar 18 | 168,068 | 14,017 | 28,486 | 14,533 |
| 31 Dec 17 | 147,592 | 16,268 | 28,181 | 10,207 |
| 30 Sep 17 | 137,770 | 16,140 | 23,229 | 10,207 |
| 30 Jun 17 | 133,126 | 16,213 | 21,103 | 10,207 |
| 31 Mar 17 | 132,428 | 15,914 | 20,455 | 10,207 |
| 31 Dec 16 | 132,490 | 16,840 | 21,700 | 8,019 |
| 30 Sep 16 | 129,950 | 17,222 | 21,345 | 8,019 |
| 30 Jun 16 | 127,054 | 16,421 | 20,897 | 8,019 |
| 31 Mar 16 | 123,492 | 17,155 | 19,604 | 8,019 |
| 31 Dec 15 | 117,641 | 16,353 | 20,671 | 6,109 |
| 30 Sep 15 | 114,210 | 15,554 | 19,637 | 6,109 |
| 30 Jun 15 | 109,716 | 15,706 | 18,302 | 6,109 |
| 31 Mar 15 | 105,454 | 14,053 | 17,903 | 6,109 |
| 31 Dec 14 | 102,083 | 13,064 | 18,525 | 5,170 |
| 30 Sep 14 | 97,279 | 12,713 | 17,935 | 5,170 |
| 30 Jun 14 | 93,041 | 11,860 | 17,618 | 5,170 |
| 31 Mar 14 | 89,823 | 12,192 | 16,582 | 5,170 |
| 31 Dec 13 | 87,423 | 13,017 | 16,226 | 4,550 |
Kaliteli Kazançlar: 4887 has high quality earnings.
Büyüyen Kar Marjı: 4887's current net profit margins (10.6%) are higher than last year (6.1%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 4887's earnings have declined by 17.4% per year over the past 5 years.
Büyüme Hızlandırma: 4887's earnings growth over the past year (41.9%) exceeds its 5-year average (-17.4% per year).
Kazançlar vs. Sektör: 4887 earnings growth over the past year (41.9%) exceeded the Pharmaceuticals industry 38.7%.
Özkaynak Getirisi
Yüksek ROE: 4887's Return on Equity (6.2%) is considered low.